Erste Asset Management Gmb H Chemo Centryx, Inc. Transaction History

Erste Asset Management Gmb H

$8.35 Trillion
Q3 2024

Shares

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 Nov 26, 2024	SELL	N/A	-35,500 Closed	0 $0
Q4 2022 Nov 26, 2024	SELL	$0.0 - $51.99 $0 - $1.85 Million	-35,500 Closed	0 $0
Q3 2022 Nov 26, 2024	BUY	$22.17 - $51.8 $787,035 - $1.84 Million	35,500 New	35,500 $1.83 Billion
Q2 2022 Nov 26, 2024	BUY	$15.36 - $27.51 $545,280 - $976,605	35,500 New	35,500 $905 Million
Q1 2022 Nov 22, 2024	BUY	$22.22 - $39.12 $422,180 - $743,280	19,000 Added 115.15%	35,500 $888 Million
Q4 2021 Nov 22, 2024	BUY	$18.38 - $40.5 $303,270 - $668,250	16,500 New	16,500 $598 Million
Q3 2021 Nov 22, 2024	SELL	$13.18 - $19.83 $573,330 - $862,604	-43,500 Reduced 72.5%	16,500 $323 Million
Q4 2020 Nov 22, 2024	SELL	$47.25 - $65.16 $708,750 - $977,400	-15,000 Reduced 20.0%	60,000 $3.69 Billion
Q3 2020 Nov 22, 2024	BUY	$46.35 - $61.69 $3.48 Million - $4.63 Million	75,000 New	75,000 $4.01 Billion
Q4 2019 Nov 22, 2024	BUY	$6.81 - $39.55 $463,080 - $2.69 Million	68,000 New	68,000 $2.46 Billion

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.